Li D, Shi W, Wang T, Tang H (2018) SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta-analysis
As for the culture environment in vitro, where only AML cells are present, orid-liposome-MAL can non-competitively enter all AML cells, causing REDOX imbalance and exerting its anti-tumor effects
Addresses it specifically
The high price of GLP-1 drugs could be substantially reduced in the future once they come off patent thereby allowing for the introduction of biosimilars
It is a modified version of insulin-like growth factor-1 engineered to: Resist binding proteins Remain active longer in circulation Increase tissue exposure Once administered, IGF-1 LR3 binds directly to IGF-1 receptors in tissues throughout the body
While more research is needed, the data hint at a potential protective effect on joint tissues themselves